Marcel R.M. van den Brink

Marcel R.M. van den Brink
Born November 14, 1960
Oegstgeest, Netherlands
Alma mater University of Leiden, The Netherlands
Spouse(s) Lia Palomba, MD
Children Lucas van den Brink, Alessandro van den Brink
Scientific career
Fields Allogeneic Bone Marrow Transplantation, Hematology, Oncology, Immunology
Institutions Memorial Sloan Kettering Cancer Center, Sloan Kettering Institute, Weill Graduate School of Medical Sciences

“Marcel R.M. van den Brink” is a Dutch hematologist and researcher who is an expert in Hematopoietic stem cell transplantation for cancer patients. He is Head of the Division of Hematologic Malignancies, Alan Houghton Chair in Immunology[1], Attending on the Bone Marrow Transplantation Service, and Member at Memorial Sloan Kettering Cancer Center (MSKCC) in New York, New York. He holds joint appointments at Sloan Kettering Institute’s Immunology Program, the Department of Medicine at MSKCC, and is also Professor of Medicine and Immunology at Weill Cornell Graduate School of Medical Sciences [2]. He is also the Co-Director[3] of the Parker Institute for Cancer Immunotherapy[4] (PICI) at Memorial Sloan Kettering[5].

As a physician-scientist, van den Brink studies Allogeneic Bone Marrow Transplantation both in the clinic and the laboratory.

Biography

Born in Oegstgeest, the Netherlands on November 14, 1960, van den Brink obtained his M.D. and Ph.D. cum laude from the University of Leiden in the Netherlands. He completed a postdoctoral fellowship at the Pittsburgh Cancer Institute in Pittsburgh, Pennsylvania, and then completed an internship and residency at Duke University Medical Center in Durham, North Carolina. From 1994-1997, van den Brink was a Clinical Fellow in Hematology and Oncology at Beth Israel Deaconess Medical Center and a Clinical Fellow in Medicine at Harvard Medical School in Boston, Massachusetts. He then carried out a post-doctoral fellowship with Dr. Steven J. Burakoff, MD at the Dana Farber Cancer Institute in Boston, MA from 1995-1999. He was recruited to Memorial Sloan Kettering Cancer Center in 1999 and was the Chief of the Adult Bone Marrow Transplantation Service from 2004 until 2008, when he became the Head of the Division of Hematologic Malignancies. Under his leadership this Division was reorganized into 5 services (Leukemia, Lymphoma, Myeloma, Bone Marrow Transplantation and Benign Hematology) and has grown to one of the largest programs dedicated to malignant hematologies in the world with currently >80 faculty members.

He was a Director of the American Society for Blood and Marrow Transplantation and currently serves on the Board of the Deutsche Knochen Mark Stiftung (DKMS) [6].

Research

Areas in which van den Brink has published research include the development of strategies to enhance post-transplant immune reconstitution[7], such as Interleukin-7[8], Keratinocyte Growth Factor, Sex Steroid Blockade, Interleukin-22 (IL-22), BMP4 and adoptive cell therapy with precursor T cells [9] or endothelial cells; novel insights in the pathophysiology of graft-versus-host disease (GVHD), such as the role of T cell cytolytic pathways, intestinal homing molecules, donor-derived neovascularization, and more recently, intestinal microflora[10]; and development of novel types of chimeric antigen receptors[11].

Awards

In recognition of his achievements, Dr. van den Brink has been awarded the Physician Scientist Award of the Howard Hughes Medical Institute, the Amy Strelzer Manasevit Scholar Award of the National Marrow Donor Program,[12] and the Damon Runyon Scholar Award of the Cancer Research Fund,[13] along with a scholarship from the V Foundation for Cancer Research.[14] In 2004 he was elected to the American Society for Clinical Investigation[15] and in 2013 to The Association of American Physicians.[16] Dr. van den Brink was also instrumental in the development of the first genomic profiling assay for hematological malignancies called FoundationOne™ Heme.[17]

Selected publications

  • Tsai JJ, Takahashi K, Dudakov JA, Shieh J, Singer NV, West ML, Smith OM, Young LF, Holland AM, Shono Y, Ghosh A, Tran HT, Moore MAS, van den Brink MRM. "Nrf2 regulates haematopoietic stem cell function". Nature Cell Biology. 2013; 15(3): 309-16. PMID 23434824; PMC 3699879.
  • Hanash AM, Dudakov JA, Hua G, O'Connor MH, Young LF, Singer NV, West ML, Jenq RR, Holland AM, Kappel LW, Ghosh A, Tsai JJ, Rao UK, Yim NL, Smith OM, Velardi E, Liu C, Fouser LA, Kolesnick R, Blazar BR, van den Brink MRM. "IL-22 protects intestinal stem cells from immune-mediated tissue damage and regulates sensitivity to graft vs. host disease". Immunity. 2012; 37:339-350. (Previews in Immunity 2012; 37:196). PMID 22921121; PMC 3477611.
  • Jenq RR, Ubeda C, Taur Y, Menezes CC, Khanin R, Dudakov JA, Liu C, West ML, Singer NV, Equinda MJ, Gobourne A, Lipuma L, Young LF, Smith OM, Ghosh S, Hanash AM, Goldberg JD, Aoyama K, Blazar BR, Pamer EG, van den Brink MRM. "Regulation of intestinal inflammation by microbiota following allogeneic bone marrow transplantation". Journal of Experimental Medicine. 2012; 209:903-911. (Research Highlight in Nature Reviews Immunology 2012; 12:399) PMID 22547653; PMC 3348096.
  • Dudakov JA, Hanash AM, Jenq RR, Young LF, Singer NV, West ML, Smith OM, Holland AM, Tsai JJ, Boyd RL, van den Brink MRM. "IL-22 drives endogenous thymic regeneration in mice". Science. 2012; 336:91-95. (Perspectives in Science 2012; 336:40; Leading Edge Select in Cell 2012; 149:729) PMID 22383805; PMC 3616391.
  • Zakrzewski JL, Suh D, Markley JC, Smith OM, King C, Goldberg GL, Jenq R. Holland AM, Grubin J, Cabrera-Perez J, Brentjens RJ, Lu SX, Rizzuto G, Sant'Angelo DB, Riviere I, Sadelain M, Heller G, Zuniga-Pflucker JC, Liu C, van den Brink MRM. "Tumor immunotherapy across MHC barriers using allogeneic T-cell precursors". Nature Biotechnology 2008; 4:453-461. (commentary in Nature Reviews in Immunology 2008; 8:321) PMID 18376399; PMC 2731996.
  • Zakrzewski JL, Kochman AA, Lu SX, Terwey TH, Kim TD, Hubbard VM, Muriglan SJ, Suh D, Cabrera-Perez J, Radhakrishnan R, Heller G, Zuniga-Pflucker JC, Alpdogan O, van den Brink MRM. "Adoptive transfer of T-cell precursors enhances T-cell reconstitution after allogeneic hematopoietic stem cell transplantation". Nature Medicine 2006; 12:1039-1047. PMID 16936725.
  • Schmaltz C, Alpdogan O, Kappel BJ, Muriglan SJ, Rotolo JA, Ongchin J, Willis LM, Greenberg AS, Eng JM, Crawford JM, Murphy GF, Yagita H, Walczak H, Peschon J, van den Brink MRM. "T cells require TRAIL for optimal graft-versus-tumor activity". Nature Medicine 2002; 8:1433-1437. PMID 12426560.

References

  1. ↑ “Alan Houghton Chair”, On Cancer, News and Insights from Memorial Sloan Kettering, March 21, 2008.
  2. ↑ “WCGS”, Weill Cornell Medicine Graduate School of Medical Sciences.
  3. ↑ [ https://www.mskcc.org/talk-msk-parker-institute-co-director “A Talk with MSK's Parker Institute Co-Director” ], News and Insights from Memorial Sloan Kettering.
  4. ↑ “Parker Institute for Cancer Therapy, Parker Institute for Cancer Immunotherapy
  5. ↑ “Marcel van den Brink” Parkerici.org”
  6. ↑ “The Management Board of DKMS” Our Structure.
  7. ↑ [ http://www.mskcc.org/research/lab/marcel-van-den-brink/manipulating-immune-function “Manipulating immune function and thymus recovery”] Marcel van den Brink Lab.
  8. ↑ [ https://www.mskcc.org/blog/helping-body-recover-after-bone-marrow-transplant “Helping the Body Recover after Bone Marrow Transplant”] On Cancer, News and Insights from Memorial Sloan Kettering, June 6. 2015.
  9. ↑ [ https://www.mskcc.org/blog/new-hope-repairing-damaged-aging-immune-system “New Hope for Repairing a Damaged or Aging Immune System”] On Cancer, News and Insights from Memorial Sloan Kettering, January 12, 2018.
  10. ↑ “Microorganisms in the Gut Can Affect Cancer Outcomes” On Cancer, News and Insights from Memorial Sloan Kettering, August 11, 2016.
  11. ↑ [ https://www.mskcc.org/blog/study-suggests-ways-make-bone-marrow-transplants-safer-people-blood “Study Suggests Ways to Make Bone Marrow Transplants Safer for People with Blood Cancers”] On Cancer, News and Insights from Memorial Sloan Kettering, January 9, 2017.
  12. ↑ "Supporting researchers for post-transplant study", "Be The Match"
  13. ↑ "Damon Runyon Scholars", "Damon Runyon Cancer Research Foundation".
  14. ↑ "Grants Awarded by State", "The V Foundation for Cancer Research"
  15. ↑ "ASCI, Honoring the Physician Scientist"
  16. ↑ "Associate of American Physicians"
  17. ↑ "Foundation Medicine Launches FoundationOne™ Heme, Developed in Collaboration with Memorial Sloan-Kettering Cancer Center", "Foundation Medicine", December 7, 2013.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.